

Anti-TNFSF5/CD40L/CD154 Antibody (Letolizumab)

Introduction

Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L that was generated to express a mutant IgG1 lacking effector functions, including Fc binding and complement fixation. Letolizumab reduced rejection, thromboembolism, and prolonged survival.

Product parameters

Alternative Names	BMS-986004
Target Accession	P29965
Target	TNFSF5 / CD40L / CD154
CAS number	1450981-87-9
Molecular Weight	39 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	-
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology
www.apexbt.com
7505 Fannin street, Suite 410, Houston, TX 77054.
Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

